KALAMAZOO, Mich., June 19, 2012 /PRNewswire via COMTEX/ -- Ablative Solutions, Inc. (ASI), a privately-held company headquartered in Kalamazoo, MI with offices in Menlo Park, CA announced today that it has completed a Series A Preferred Stock financing, totaling approximately $5.3 million (including the conversion of the bridge financing completed earlier this year), to fund its unique technology platform. The round was led by BioStar Ventures and the Michigan Accelerator Fund, and included participation by multiple angel investors. Honigman Miller Schwartz and Cohn LLP served as legal advisor to ASI for the transaction.

ASI is developing a significantly different approach to Renal Denervation, a new therapy that addresses hypertension and other diseases related to overactive sympathetic nerve activity. The sympathetic nerves that run along the renal artery play an essential role in controlling blood pressure but, when overactive, contribute to hypertension. Renal Denervation has been demonstrated to reduce blood pressure in patients who are not effectively treated by medical therapy. De-activating these nerves modulates the signaling process, and helps to reduce blood pressure. Unlike other approaches to Renal Denervation, which deliver destructive energy through the entire renal artery wall, ASI has developed a unique device that targets treatment directly to the nerves that encircle the renal artery, without damaging the artery wall - a solution that ASI calls PeriVascular Renal Denervation (PVRD(TM)).

"Hypertension has an extraordinary impact on health, but it is a disease that is underappreciated. There is good reason for the excitement surrounding Renal Denervation - it produces a persistent, durable reduction in blood pressure with a minimally invasive procedure," observed Dr. Tim Fischell, CEO and CMO of ASI. "ASI seeks not only to simplify and streamline the denervation procedure, but, more importantly, to do so without damaging the vessel wall, by delivering the therapy directly to where the sympathetic nerves reside, just outside the blood vessel."

"We believe that ASI's simple, elegant approach will address the clinical need effectively," stated Dr. Vartan Ghazarossian, President and COO of ASI. "Our technology development is driven by the awareness that less is more - providing optimized ablation of the sympathetic nerve less invasively and with less equipment and a shorter procedure time." The Company projects that its clinical evaluations will begin in 2013.

ASI was founded by two proven medical device entrepreneurs, Tim Fischell, MD and David Fischell, PhD. With executive experience in both biopharmaceutical and medical device companies, Vartan Ghazarossian, PhD, is uniquely positioned to lead the development of ASI's novel device-chemistry-based therapy. Dr. Steven Almany of BioStar Ventures, a member of ASI's Board of Directors, commented: "The therapeutic potential of perivascular renal denervation is very attractive, and we are very pleased to invest in ASI's team as they develop their unique approach."

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in this offering. There will not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For more information:Vartan Ghazarossian, PhD(650) 321-6884 http://www.ablativesolutions.com

Forward-Looking Statements

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. ASI's actual results may differ materially from ASI's historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to ASI's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of ASI's intellectual property portfolio, the risk associated with obtaining the necessary regulatory approvals, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors.

http://www.ablativesolutions.com

http://www.biostarventures.com

http://www.maf-1.com

SOURCE Ablative Solutions, Inc.

Copyright (C) 2012 PR Newswire. All rights reserved

...

Renal denervation Trinidad News Portal of Trinidad and Tobago with always fresh news on sport, business, culture and entertainment.

...

DES MOINES, Iowa, June 18, 2012 /PRNewswire/ -- Today, Mom's Meals introduces its new Renal Nutrition Program,helping patients on dialysis simplify decisions about what to eat by delivering fresh-prepared, ready to heat and eat meals directly to their door. With over 26-million American adults suffering from chronic kidney disease, the struggles of everyday life, including what to eat, can feel overwhelming. On average, dialysis patients endure three treatments a week, each for several hours, and struggle to manage daily life, including the complicated dietary restrictions which come with this disease.

"One of the things we hear from dialysis patients is how difficult it is to prepare meals containing the proper potassium and phosphorous levels," said Rick Anderson, President of Mom's Meals. "Creating a menu for those with kidney disease was a natural for us since we have a dedicated nutritional services team which includes Registered Dieticians and Chefs who develop diabetic-friendly and heart-healthy meals already."  

Mom's Meals' Renal Nutrition Program provides meals designed by a renal dietitian using the National Kidney Foundation guidelines to support the unique nutritional needs of most dialysis patients.  The Program provides recommended protein amounts while restricting sodium, potassium, and phosphorus.

Most unique about the Renal Nutrition Program is that patients choose only the meals they want from a revolving menu of over 40 items.  The meals, which cost $5.99 per "entree" only and $6.99 for entree plus sides, are fresh-delivered in climate-controlled coolers.  Proprietary packaging methods allow them to stay fresh in the refrigerator for up to 18 days.  A support team, including a renal dietitian, is available to answer nutrition questions, and weekly calls are made to patients to assist with meal selection or program questions.

Mom's Meals recognizes that the nutritional needs vary for each renal disease patient. Patients should always consult with their doctor before starting any nutrition program. Mom's Meals does not claim to treat or cure kidney disease and is not a substitute for medication.

Mom's Meals, is dedicated to providing fresh meals to customers nationwide.  The company prepares, packages, and ships ready-to-heat and eat meals directly to a customer's door, delivered anywhere in the United States. For more information, visit http://momsmeals.com/

SOURCE Mom's Meals

...

Children born with one kidney are often advised by doctors not to play sports, since there is fear that if they sustain an injury to the organ, they might need lifelong dialysis.

However, those beliefs can be left behind, since the result of the analysis of a large database of sports-related injuries among varsity-level high school athletes showed that only 18 cases involved kidney injury.

Like Us on Facebook :

Or in other words, there was 1 kidney injury per one million times when an athlete hit the playing field.

"Even in the highest-risk group, kidney injury is a very rare condition," said Dr. Matthew Grinsell of the University of Utah in Salt Lake City.

"Especially with today's obesity epidemic, I am very, very reluctant to counsel somebody against physical activity," he told Reuters Health

An analysis was done by the researchers on data from the National Athletic Trainers' Association High School Injury Surveillance Study from 1995 to 1997.

The results revealed that even when athletes injured their kidneys, it was mostly a bruise and none of the injuries were serious enough to need a transplant.  Also, the ratio of head injuries to Kidney was found to be 67:1.

"We know that kidney injuries from traffic accidents are two to 10 times more common than kidney injuries from sports," Grinsell explained. "Some people have argued it might actually be more dangerous to drive to your doctor to talk about kidney injuries from sports than actually playing sports."

Grinsell however advised that it is important to make sure that children with one kidney have their organ functioning normally and that their blood pressure is not too high before sending them onto the field.

"If somebody has a passion, I really don't limit it," said Grinsell. "I push the more general safety issues, like wearing a helmet if you are a bicyclist."

The study was published in the journal Pediatrics.

...